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Abstract
Background: Large-scale sequencing experiments are complex and require a wide
spectrum of computational tools to extract and interpret relevant biological
information. This is especially true in projects where individual processing and
integrated analysis of both small RNA and complementary RNA data is needed. Such
studies would benefit from a computational workflow that is easy to implement and
standardizes the processing and analysis of both sequenced data types.
Results: We developed SePIA (Sequence Processing, Integration, and Analysis), a
comprehensive small RNA and RNA workflow. It provides ready execution for over 20
commonly known RNA-seq tools on top of an established workflow engine and
provides dynamic pipeline architecture to manage, individually analyze, and integrate
both small RNA and RNA data. Implementation with Docker makes SePIA portable and
easy to run. We demonstrate the workflow’s extensive utility with two case studies
involving three breast cancer datasets. SePIA is straightforward to configure and
organizes results into a perusable HTML report. Furthermore, the underlying pipeline
engine supports computational resource management for optimal performance.
Conclusion: SePIA is an open-source workflow introducing standardized processing
and analysis of RNA and small RNA data. SePIA’s modular design enables robust
customization to a given experiment while maintaining overall workflow structure. It is
available at http://anduril.org/sepia.
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Background
Massively parallel cDNA sequencing technology (RNA-seq) generates vast amounts of
biological data and has become a primary means of transcriptome analysis. A number
of RNA-seq protocols exist to produce total RNA, poly(A)-derived RNA and small RNA
data. The choice of RNA-seq protocol affects the design principles implemented in the
computational analysis of the data [1]. Accordingly, strategies have been developed to
computationally identify and interpret biological information from different RNA-seq
data types [2–4]. However, these strategies are generally limited to a single data type or
integration alone, with a set number of tools and little to no support for extensibility.
Furthermore, the accuracy of existing tools often varies across datasets and data types,
making a consensus on best practices for processing and analysing sequenced data chal-
lenging to reach. A solution to this issue is a modular computational platform that allows
testing, development, and easy replacement of methods.
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Here, we present the open-source workflow for automated RNA-seq processing, inte-
gration and analysis (SePIA). It provides essential pipeline infrastructure for efficient
and reproducible analysis of total RNA, poly(A)-derived RNA, small RNA, and inte-
grated microRNA (miRNA) and mRNA data. It does so by (1) expanding the utility of the
pipeline engine Anduril [5] to include a bundle of RNA-seq tools and (2) by providing
users with the framework in which to best utilize the tools: a set of executable but highly
configurable pipeline scripts that, together, form one compendious workflow.
Currently, over 20 existing software and packages (Table 1) are incorporated in SePIA.
These tools represent commonly known and establishedmethods developed for sequenc-
ing data. Components within pipelines provide users the option to choose amongst
functionally similar tools, while built-in transitional steps standardize the input and out-
put formats of these tools for seamless data flow. Through these components, processes
are standardized and overall workflow structure is maintained. While the choice of tools
is solely up to the user and the needs of their data, the workflow offers the convenience of
ready implementation.
Included in the workflow are two novel processes for improved integrated analysis of
miRNA andmRNA datasets. The first is a database creation pipeline able to integrate and
query multiple, user-downloaded public resources (e.g. of predicted and experimentally
validated mRNA targets of miRNAs) or custom lists of regulatory pairs. The second is
a pair of target prediction components utilizing sequence complementarity to discover
likely targets of putative novel miRNAs and to increase the number of potential mRNA
targets of known miRNAs.
The SePIA workflow was designed for straightforward execution of pipelines by users
of all programming experience. Defining inputs and parameters, for example, is the min-
imum requirement by both graphical and command-line RNA-seq pipelines, requires no
programming, and is done in a single settings file. Installation of the workflow is also sim-
plified to a few copy-and-paste command-lines on a Linux distribution. However, in order
to make changes to the pipeline execution and take advantage of other tools available with
the workflow, some programming experience is required. Fortunately for method devel-
opers and users willing to do some learning while doing, features implemented with the
workflow provide a stable environment for straightforward modification and addition of
components in a pipeline. Examples, including a fully executable demo case, installation
instructions, component documentation, workflow scripts and resources are available on
the website, http://anduril.org/sepia.
Implementation
SePIA is an open-source workflow designed to meet three general aims: (1) to make
available a selection of state-of-the-art RNA-seq tools and methods with minimal
effort to run, (2) to automatically organize computational results in reproducible,
presentable, and easy-to-use formats for in-depth investigation, and (3) to provide
a framework for integrated RNA and small RNA processing and analysis. To meet
these aims, SePIA relies on the following features supported by the workflow engine
Anduril [5]:
• Abstraction of multiple tools and executable scripts written in different programming
languages, sparing the user the task of familiarizing with each language.
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Table 1 Command-line executable software readily implemented in the SePIA workflow and used
with the case studies
Module Component Software Reference
Preprocessing Adaptor and quality
trimming
FastX-Toolkit hannonlab.cshl.edu/
fastx_toolkit/
Trimmomatic [62]
Trim Galore www.bioinformatics.
babraham.ac.uk/projects/
trim_galore/
Quality statistics FastQCa www.bioinformatics.
babraham.ac.uk/projects/
fastqc
Read mapping Align sequences to a
reference
BWA [63]
Tophat [64]
Bowtie [13]
Bowtie2 [65]
STAR [7]
Alignment sorting
and conversion
SAMtoolsa [66]
Picard toolsa broadinstitute.github.io/
picard
Alignment statistics RNA-SeQC [67]
RSeQC [68]
Expression Mapped reads
quantification
HTSeq [69]
Cufflinks [70]
Analysis Variant calling Bambino [35]
and annotation ANNOVAR [71]
Differential expression Cuffdiff [18]
R bioconductor
packages for
differential expression
DESeq [15]
DESeq2 [72]
DEXseq [73]
EdgeR [14]
novel miRNA
discovery
miRanalyzer [74]
miRDeep2 [75]
miRNA-mRNA integration R package for
SQLite query
sqldfa [76]
Pathway impact
analysis
SPIA [77]
Software marked with a are mandatory requirements for the minimum execution of a module. A list of software pre-installed
within SePIA’s Docker image and the full range of currently available components can be accessed through the website
• Optimization of available computer resources, including parallelization of
independent components.
• Modularity. Tools and resources are implemented as independently executable
components made linkable through the standardization of input and output formats.
• Verbose logs of executed processes for directive error tracking.
• Implementation of filters and fail safes, including data type checking, to prevent
execution and consequent failure of software with invalid/insufficient input.
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• An ability to pick-up processes from a previous state, in case of failure or other
interruption, and avoiding unnecessary re-execution of parts of a pipeline.
• Complete and easily searchable documentation of all components and their
parameters.
Anduril’s Java-based workflow configuration language allows users to set component
resources and parameters, and to connect data between otherwise independent com-
ponents for seamless data flow. The configuration language makes no contribution to
low-level processing, providing a clear separation between workflow development and
application development. Anduril also contains programming interfaces that support the
implementation of custom components written in any command-line executable program
such as Bash, Java, R, Python, Perl and MATLAB. Users can thus create custom scripts
for a pipeline in their preferred language.
SePIA is built on Anduril and thus inherits the necessary infrastructure and features
for reliable large-scale data analysis. Computational overhead produced by a workflow
built on Anduril versus simple Bash scripting was explored by Rantanen et al. [6], with
the underlying pipeline engine showing improved processing (and dramatically reduced
re-processing) time at the cost of computational space for additional files created. These
include log files on a global and component level containing verbose output from the
executed process, parameters used, input and output file locations. A folder is gener-
ated for each process instance executed and files created are immediately accessible after
generation. These additional files push up the computational overhead but facilitate pro-
cess tracking by the workflow engine, fast re-execution, user error-debugging, and future
reproduction of results. A summary of time and disk space usage of components, as well
as a list of component instance folders produced, are generated outputs of pipelines to
further aid users in finding intermediary files and allocating computational resources.
Though the underlying pipeline engine does not enable parallel computing nor reg-
ulate computational resources by default, a user can specify these in SePIA execution
scripts with normal and locally-defined command-line switches in the header or as input
string parameters to select components (e.g. memory-intensive read-mapping software).
An example enabling multiple threads is described with performance statistics in the
Discussion.
SePIA runs on Linux and assumes all software and dependencies are discoverable in
PATH prior to script execution. While some tools and libraries are installed with Anduril
and the bundle of RNA-seq components (e.g. R and Python packages), it was not pos-
sible for all tools incorporated for use with the workflow. Manually setting up a Linux
machine to run SePIA, especially one with custom settings, can thus be daunting and
time-consuming.
To simplify installation and enable immediate use of the SePIA workflow, a Docker
image was made of a Ubuntu 14.04 distribution with Anduril and essential sequencing
tools pre-installed. Docker (http://www.docker.com) is an open-source implementation
of lightweight Linux containers in which an ’image’ of an application and all its depen-
dencies are packaged to run in a standardized way. Local folders can also be mounted to
Docker containers, which means SePIA can use all the computational resources within
the container but access and write files locally. This includes essential log files for work-
flow process tracking. Docker thus provides a convenient and static environment for
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pipelines to be executed in with guaranteed result reproducibility. Installation and set
up is reduced from multiple required dependencies to Docker and any software for
optional execution scripts (e.g. novel miRNA discovery) that a user may wish to run. A
demo is available on the website showing how, with a mere six lines of copy-and-paste
code, one can install Docker with SePIA and run a complete small RNA pipeline from
pre-processing to differential analysis.
Use of parallel computing and resource management with Anduril and memory-
consuming software such as STAR [7], however, may be limited within a Docker container
despite available run configurations. For some processes in the workflow, manual instal-
lation of Anduril and select software may be more convenient. Availability of disk space
is also a common problem with RNA-seq. Both issues are addressed with the modular
design of the SePIA workflow, which allows for the pipeline and not the dataset to be
broken into more digestible parts. This way, a dataset can be processed as a whole by
independently executable, compartmentalized, and connectible parts. The entire RNA
pipeline, for example, is divided into three script files with individually specified execution
folder locations for easier management. Each subsequent script references the previous
script’s output to continue the pipeline.
Software design
A major feature of SePIA’s design and implementation is that it facilitates rapid meth-
ods development and parameter fine-tuning, providing users a convenient means to
establish their own standard for processing and analyzing different RNA-seq data.
While interactive RNA-seq applications such as wapRNA [4], sRNAbench [8], and
Galaxy Browser [9] are attractively accessible as they require little to no prior knowl-
edge of programming or installation of software, they are limited in scalability and
adaptability to large and complex experiments. The modular framework of SePIA sim-
plifies the task of implementing changes to workflow processes or execution by making
direct configuration of driver scripts possible. The workflow can thus be adjusted to
work with the data, rather than the reverse which is required by graphical applica-
tions. An example is described in Additional file 1, Case 1. Transitional tools simplify
and automate file modification within the workflow to meet rigid data type and for-
mat restrictions of third-party software, eliminating the need for manual manipulation
between steps.
The workflow is designed to readily incorporate the use of over 20 tools but is not lim-
ited to these tools. More can be found in the bundle of RNA-seq components that comes
with SePIA. Survival and pathway analysis, for example, are available components not
included in the pipeline scripts by default. Programming interfaces can be implemented
to pipelines like components to include, for example, executable libraries. Combined with
the workflow’s modular design, these provide a straightforward means to incorporate any
tool or method to a pipeline.
Primary execution scripts are configured to reference a master settings file for a given
pipeline. These text files contain a number of parameter options and inputs that enhance
the workflow’s ability to accommodate a range of RNA-seq features, but also emphasizes
the importance of users first understanding the features of their data and what they aim to
get out of it before choosing parameters. For example, users interested in novel transcripts
may choose TopHat or STAR as their aligner because of their transcript discovery mode.
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To aid users, a brief explanation about when, where and what each parameter is for is
given in the settings as a guideline.
Components in the workflow are organized into five functional modules representing
general steps in an RNA and/or small RNA pipeline (Fig. 1): RNA-seq data preprocess-
ing, read mapping, expression quantification, analysis, and integration. RNA-seq data
preprocessing trims adapter and low quality bases from the sequenced reads. Read map-
ping is done with one of five alignment software and provides methods for estimating
parameters such as insert size. Mapped reads are quantified and normalized for gene,
transcript, and exon-level expression. Differential expression analysis is performed and,
depending on RNA-seq type, optional sequence analysis. This includes novel miRNA and
small RNA discovery, variant calling and functional annotation, and gene fusion detec-
tion. Further integrated analysis of miRNAs and target mRNAs incorporates third-party
target database resources, built-in target prediction based on seed-complementarity, and
pathway analysis.
Summary statistics and result files from each module are collected in the output folder
of a pipeline’s execution path. Contents of this folder are refreshed on each execution
of a pipeline. These outputs are then retrieved across multiple execution paths with the
SePIA reporting scripts and organized into easy-to-browse HTML reports. Further detail
on these reports are provided in Additional file 1.
Modules in SePIA are executed sequentially but it is also possible to execute them inde-
pendently, allowing users to import previously processed or analyzed data (e.g. already
trimmed reads, quantified expression matrices, predefined lists of interesting genes) for
further investigation. SePIA is structured to allow for the execution of components as
soon as resources and input becomes available (e.g. expression quantification of a sample
starts once the alignment file is ready even though other samples are still being aligned),
and components that require multiple inputs to be processed (e.g. differential expression
analysis) will wait to execute when all inputs are ready. This prevents downstream analysis
with incomplete data, and ensures each component produces valid results in a module.
Fig. 1 SePIA workflow summarized in five generalized modules. Each module contains a brief description of
the major steps performed in each pipeline. For example, the ’double-pass’ alignment means reads are
mapped first to the whole genome and then to a reference transcriptome. Colors used represent common
processes (black), processes specific to small RNA (purple) and RNA (green) data, and the main outputs of the
modules (grey). Incorporation of a miRNA-target mRNA database to the workflow is represented in blue.
Interesting molecules of the analysis module are defined as differentially expressed, predicted, or mutated
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Preprocessing RNA and small RNA
The mandatory input files for SePIA’s first module are tab-delimited text files containing
the following information: unique, per-sample IDs and the corresponding path to unpro-
cessed .fq/.fastq file. Two optional columns can be added to provide further identification
of ‘treatment’ and ‘sample’ information, which are required for differential analysis and
visualization. Example inputs are provided in Additional file 2.
Three adapter and quality trimmers are implemented in SePIA to cover different fea-
tures in processing RNA and small RNA sequences [10]. To determine and verify optimal
trimming parameters, quality checks are first performed on raw fastq files by FastQC.
Read statistics, adapter trimming, and quality control are then done for each input file in
parallel. SePIA parameters include two user-defined filters to identify and exclude sam-
ples with poor quality scores or with insufficient number of reads surviving from the
adapter and quality trimming.
The output of this module includes an HTML report summarizing preprocessing statis-
tic, FastQC results organized by patient sample or metric type (Fig. 2a), and an array of
samples with high-quality processed reads– the primary input for the next module.
Readmapping and expression quantification
SePIA is equipped to use any of the five available sequence alignment tools listed in
Table 1, though using novel tools is possible and straightforward to implement. For
Fig. 2 A snapshot of the reports created by SePIA for the case studies. a Small RNA preprocessing report for
Case II, including FastQC results organized by patient sample. b, c Alignment and expression statistics for
Case I with some standard visualization. d The searchable miRNA-target mRNA report for Case II
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read mapping, discovery of potentially novel transcripts, and quantification of alternative
splicing, a ‘double-pass’ implementation of STAR aligner is used [7, 11]. A ‘double-pass’
alignment is also used for small RNA data using Bowtie [12, 13] to extract a subset of
reads that do not map to existing miRNA annotations for independent novel miRNA and
other small RNA discovery.
Mapped reads from RNA data are then quantified for expression at a gene, transcript,
and/or exon level using HTSeq and Cufflinks; and for small RNA data at a mature or
transcript miRNA level using HTSeq. While Cufflinks produces scaled expression in the
form of fragments per kilobase per million (FPKM), HTSeq produces ‘raw counts’ that
generally require further normalization to be informative. Three methods are imple-
mented in SePIA for this purpose: counts-per-million with edgeR [14], library-size factor
scaling with DESeq [15], or upper-quartile normalization. While the former two rep-
resent standard scaling approaches, the latter is a robust alternative for more complex
datasets [16].
Small RNA annotations can be extracted from Ensembl general transfer format (.gtf )
files and referenced for read quantification. Alternatively, miRNA annotation files in gen-
eral feature format (.gff3) can be directly downloaded from the miRBase website (http://
www.mirbase.org). Though they share a lot of the same genomic information, differences
in miRBase’s annotation format compared to Ensembl makes it incompatible for use with
HTSeq for expression quantification. SePIA solves the problem with a Boolean settings
parametermirbase_gff that, when true, calls a transitional step to reformat the .gff3 file to
resemble that of an Ensembl .gtf file. This enables expression quantification on a mature
miRNA level not possible with Ensembl transcript annotation.
Outputs from this module include BAM alignment files, a report with alignment statis-
tics (Fig. 2b and Additional file 1: Table S7), ‘raw count’ as well as normalized expression
in basic and log2-transformed FPKMs on multiple genomic levels, and expression statis-
tics (Fig. 2c). Both STAR and TopHat can be configured to detect fusion genes and provide
the chimeric reads as additional output.
Sequence and differential expression analysis
The analysis module of the SePIA workflow can be configured with different goals for
each dataset. Given that RNA-seq provides base level resolution, variant calling can be
performed and functionally annotated to find mutations in expressed genes that may play
a role in a disease [17]. Differential expression analysis can be performed with one of
several Bioconductor R packages or Cuffdiff [18].
Demonstrating the ease in which SePIA can produce comparable results from different
methods, multiple differential expression analyses can be executed in parallel by a sin-
gle RNA-seq component (DEan). If a user defines a complex dataset with more than two
groups in the sample and treatment information, differential analysis will be performed
on all paired combinations of treatment groups. These are particularly useful for bioin-
formatics developers, who are often required to gain results from multiple approaches or
with multiple parameter values for comparison.
Novel miRNA and other small RNA discovery is performed on the subset of sequenced
small RNA mapping to the genome. MiRanalyzer and miRDeep2 are currently imple-
mented in the workflow. The former features detection of low-abundance candidates and
the latter’s conserved approach reduces false positives [19]. Counts of reads mapping
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to putative miRNAs are produced for each patient sample and merged by SePIA
into overlapping genomic regions. This broadens novel miRNA discovery to include
genomic regions that may contain other small RNAs encoding miRNAs or having
putative sequence features similar to miRNAs, such as small-nucleolar RNAs (snoR-
NAs) [20, 21]. The result is a single count matrix of sequence regions with putative
miRNA-like function. Components for normalization and differential expression anal-
ysis are then easily implemented with this count matrix as input. Further annotation
and hierarchical clustering of differentially expressed, putative novel miRNA regions
by SePIA provides relative genomic context and helps identify potentially interesting
regions.
Integrated miRNA-mRNA analysis
To date, miRNAs have the most consistent and well-characterized regulatory function
of all known small RNAs. To evaluate this function for differentially expressed miR-
NAs, however, their mRNA targets must first be identified. One approach that produces
encouraging results is to integrate known miRNA- and mRNA-level expression data with
in silico target predictions to filter subsets of potentially interesting miRNAs and their
target genes in a particular experiment [22–24]. In SePIA, correlation is used to iden-
tify mRNA expression profiles showing a significant, inverse relationship to differentially
expressed miRNAs.
For target prediction, SePIA has an optional pipeline, MirTPdb, to create, query,
and maintain an integrated SQLite database of predicted and validated miRNA-mRNA
pairs from public resources. MirTPdb consists of two components: one to create the
SQLite database, and one to query it. The database produced for our case study is com-
prised of predicted miRNA-mRNA pairs downloaded from TargetScan [25], MicroCosm
[26], DIANA-microT-CDS [27], and PITA [28]. It also includes experimentally validated
miRNA-mRNA pairs downloaded from release 4.5 of miRTarBase [29] further curated
by us, and is available for download on the SePIA website. Multiple target prediction
databases were chosen to gain sufficient representation of empirically derived ‘rules’ by
which miRNAs are considered to function in the prediction algorithms. The most preva-
lent of these rules searches for a degree of sequence complementarity between a miRNA’s
seed region of 2-7nt, and the 3’UTR of a target mRNA.
To identify targets of predicted novel miRNA regions or to expand the set of targets
for known miRNAs, target prediction based on miRNA sequence complementarity was
developed for SePIA’s integration module. All known and novel miRNA-mRNA pairs
with highly anti-correlated expression profiles and support for their functional interaction
from target databases or sequence complementarity analysis are reported in an easy-to-
browse website (Fig. 2d). Users can view all mRNA targets of a single miRNA (or vice
versa) and browse results by correlation coefficient, supporting evidence for regulation,
or expression fold change. A full example of this report is available at http://anduril.org/
sepia.
Integrated analysis of miRNAs and mRNAs is a dynamically developing field of RNA-
seq research. While correlation is the most common approach incorporated to analyses
identifying likely miRNA targets, it is not the only approach. Demonstrating how the
workflow’s modular pipeline architecture supports customized application and methods
development, we also include an alternative Bayesian approach to identifying functional
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miRNA and mRNA relationships with GenMir++ [30] as an optional extension of the
integration module. It is briefly described in the Discussion.
Results
We demonstrate SePIA’s broad utility with three publicly available Illumina RNA-seq
datasets consisting of paired-end total RNA, poly(A) RNA, and single-end small RNA.
The first dataset comprised of total RNA-extracted mRNA from 17 tumor and 3 nor-
mal breast samples, sequenced with Illumina HiSeq, from the Gene Expression Omnibus
(GSE52194, [31]). The second and third datasets comprised of Level 1 data of 144
poly(A)-extracted mRNA samples (129 tumor, 15 normal breast tissue) and 149 miRNA
samples (133 tumor, 16 normal breast tissue) downloaded from The Cancer Genome
Atlas consortium [32]. Per-sample details are summarized in Additional file 2.
We organize the datasets into two case studies: the first to showcase SePIA’s utility for
transcript-level sequence analysis; the second to demonstrate integration of mRNA and
small RNA data.
Case I: Breast cancer analysis of mRNA extracted from totalRNA
For this RNA-seq dataset we performed preprocessing, read mapping, expression quan-
tification, and differential expression analysis on a gene and transcript level. One tumor
sample (SRR1027187) was discarded during preprocessing because less than 60% of the
reads survived quality and adapter trimming. Successfully trimmed reads were mapped
to the human genome NCBI38v76 using STAR aligner. A detailed summary of sequence
and expression analysis results, as well as parameters used are provided in Additional
file 1. Briefly, the majority of genes found to be differentially expressed between normal
and tumor breast tissue were protein coding, with variable detection of small non-coding
genes by Cuffdiff and DESeq2. 23 genes were found to have preferential usage of one
isoform over others in normal versus tumor samples (Additional file 1: Table S2) and
include breast cancer-associated genes EIF3L and EEF2 [33, 34]. DEXSeq identified 546
genes with at least one case of differential exon usage, with a minimum log2-fold change
of two.
Variant calling was implemented using Bambino [35] and filtering steps according to
Piskol et al. [17] and GATK are implemented in SePIA to minimize the number of false
positive calls. We found a total of 85,664 indels and 16,882 SNVs. From these, 2,534 are
known post-translational editing sites. When comparing variants found in tumor against
normal samples, 341 variants were overrepresented in tumor tissue comprising 246 genes.
The list of the variants found in exonic regions in protein coding genes is included in
Additional file 1: Table S4.
Case II: Integrated breast cancer analysis of miRNA and poly(A) derived mRNA datasets
From the 144 mRNA samples, 138 passed quality control with one sample discarded for
having mostly poor quality sequences (i.e. an average quality score less than 20), and five
samples discarded for having less than 60% of reads surviving trimming, an indicator of
poor sequence content. Of the TCGA miRNA dataset, 148 of 149 samples passed quality
control, with one sample discarded for having less than 20% of reads surviving trim-
ming. The low percentage indicates either poor sequence content after trimming or poor
miRNA representation in the sample.
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Preprocessing, read mapping, and expression quantification of poly(A)-derived mRNA
data was performed with the same tools as in Case I. 4,170 genes and 2,257 mRNA tran-
scripts were found to be differentially expressed between normal and tumor breast tissue
with a conservative false-discovery rate of 0.05. Furthermore, 48 genes had preferen-
tial usage of one isoform over others in normal versus tumor samples (Additional file 1:
Table S3).
MiRNA sequences were aligned with Bowtie to known miRNA transcripts (miRBase,
version 21). On average, 95% of our preprocessed small RNA map to the genome, with
approximately 1–33% mapping to something other than known miRNAs in the genome.
Eipper–Mains et al. [36] suggests some of these reads map to other small RNAs, which
concurs with our rationale to extend novel miRNA discovery to include other small
RNAs.
Though SePIA can quantify miRNA expression on a mature and precursor level, only
mature miRNAs were calculated for this study. Lengths of trimmed reads were normally
distributed around 22nt, indicating content consistent with mature miRNA sequences.
The human annotation file hsa.gff3 was retrieved directly from miRBase to create the
reference for HTSeq quantification. 28% (799/2,813) of all human mature miRNAs were
expressed in the normal and tumor breast tissue samples with at least two mapped reads,
consistent with tissue-specific expression characteristic of miRNAs [37].
Demonstrating the ease in which SePIA can produce comparable results from differ-
ent approaches, three methods were used for differential expression analysis: DESeq,
EdgeR, and upper-quartile normalized t-test. Bioconductor package edgeR [14] identified
the most differentially expressed mature miRNAs (n=408 with false discovery rate <0.05)
shared by all three methods.
Novel miRNA and other small RNA discovery utilizing miRanalyzer produced a matrix
of 442 putative novel miRNA regions between 72 and 159nt in length. In comparison,
the range of known miRNA transcripts in miRBase v.21 is between 40 and 179nt. Anal-
ysis identified 33 of these putative novel miRNA regions to be differentially expressed
between normal and tumor breast tissue (false-discovery rate <0.05). Encouragingly, man-
ual inspection of these novel regions revealed five overlapping snoRNAs (SNORA56,
SNORA69, SNORD95, SNORD49, SNORD82), one overlapping a predicted novel miRNA
(AL161626.1), one overlapping a known miRNA not in miRBase (FP236383.10), and one
small zinc-finger protein (ZNF813). SnoRNAs that encode miRNAs or have miRNA-
like function have been previously reported [20, 21]. Independent alignment of small
RNA sequences to small non-coding RNA transcripts with Ensembl IDs (size-selected
for 15–80nt) revealed an additional 1.3% of total processed reads mapped to small RNAs
other than miRNAs, particularly snoRNAs with a C/D box and transfer RNAs. Similar
percentages were reported by Eipper–Mains et al. [36].
In this study, we implement the integration module to further evaluate 408 differen-
tially expressed miRNAs (plus 33 differentially expressed putative miRNA regions) and
their roles in breast cancer. Integration was performed on 123 tumor and 15 normal
samples sharing patient sample IDs in both the TCGA miRNA and mRNA datasets. Tar-
get transcripts of the differentially expressed miRNAs were identified with our target
prediction database, with anti-correlated expression (Pearson coefficient <-0.4 and false
discovery rate <0.01) [38, 39] and with a minimum absolute log2 fold-change of 0.5. A
total of 4,208 pairings between 174 differentially expressed miRNAs and 915 transcripts
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with anti-correlated expression and supporting annotation. We used SePIA’s sequence
complementarity components to increase the total number of putative targets for our
differentially expressed miRNAs and gained an additional 8036 pairings containing 217
miRNAs and 1809 gene transcripts not recorded in our integrated target database.
We found 256 differentially expressed transcripts predicted by SePIA’s sequence com-
plementarity components to have binding motifs for our 33 putative novel miRNAs
and anti-correlated expression (Pearson coefficient<-0.4 and false discovery rate <0.01).
Stringent binding motifs (8mer, 7mer-m8, 7mer-a1) were found in 115 of the 373 pre-
dicted miRNA-mRNA pairs. These include two down-regulated tumor suppressor genes
CCNDBP1 [40] andAHNAK [41] targeted by a putative miRNA region in chr2:17753239-
17753361 (-), and two overexpressed genes MYO10 [42] and CCNB2 [43] targeted by
a putative miRNA region in chr5:181243270-181243420 (-), which overlaps SNORD95.
These genes are known to play essential roles in breast cancer tumorigenesis, invasion
and metastasis [40–43].
Themir-17/92 cluster of oncogenes
Amongst our list of differentially expressed miRNAs are members of the mir-17/92 clus-
ter, the most frequently activated miRNA cluster in cancers. All six members (miR-17,
miR-18a, miR-19a, miR-20a, miR-19b and miR-92a) are located within the third intron
of the C13orf25 gene at 13q31.3, and are well-known promoters of cell proliferation,
cell survival, and angiogenesis [44]. Indeed, these miRNAs were significantly overex-
pressed in our case study’s breast tumor tissues. This highly-conserved sequence cluster
also has two human paralogs whose members were also overexpressed in breast tumors
(specifically, miR-106a, miR106b, miR-93, miR-20b, miR-92a-2 andmiR-363) and support
complementary roles to the mir-17/92 cluster in tumorigenesis [45].
Three commonly predicted targets of the miR-17/92 cluster showing anti-correlated
expression are tumor suppressors TGFBR2 [46], DCN [47], and CAV1 [48] which were
under-expressed in the breast tumor tissues. This is consistent with previous studies pre-
senting the mir-17/92 cluster as inhibitors of TGF-beta signaling via regulation of key
pathway genes [46]. Anti-correlated and predicted miRNA-target gene pairs of the TGF-
beta signaling pathway andmir-17/92 cluster are illustrated in Fig. 3. Interestingly, SePIA’s
integrated analysis reveals putative differences in miRNA co-regulation of TGFBR2 and
DCN : 9 of the 10 expressed members appear to target both of the known transcripts of
TGFBR2, the ligand-binding receptor for all members of the TGF-beta family, while all
10 miRNAs appear to co-regulate four different transcripts of DCN, an anti-angiogenic
factor in breast cancer [47]. Similarly, members of the mir-17/92 cluster and paralog clus-
ters were predicted by our sequence complementarity components to co-regulate three
different transcripts of CAV1, whose role in breast cancer has been extensively studied
[48, 49] but had not been previously linked to miR-17/92.
Discussion
The SePIA workflow allows analysis of paired-end total RNA, poly(A)-derived RNA, and
single-end small RNA data. All three data types were processed by the same RNA-seq
components at common steps in the workflow, such as preprocessing and alignment,
to produce standardized outputs. The ease in which SePIA’s pipelines can be extended
was demonstrated in Case I, where variant calling was performed as an additional,
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Fig. 3 Target genes of the mir-17/92 cluster and paralog clusters in the TGF-beta signaling KEGG pathway.
Target transcripts were selected to have minimum log2-fold change of 0.5 between tumor and normal
breast tissue. Node colors represent expression fold change between normal and tumor breast tissue
samples. Relationships between connected miRNA-target transcript pairs are shaded based on correlation
coefficient values. Connections between transcript and gene represent average correlation values of
contributing transcripts and their regulating miRNAs
independently-executed analysis of transcript-level data. Integrated analysis was demon-
strated in Case II, identifying biologically interesting miRNA-mRNA pairs by combining
expression correlation with in silico target predictions [24]. Though Cufflinks and HTSeq
are used in the workflow for mapped read quantification, users may prefer other tools
such as RSEM [50], eXpress [51], and BitSeq [52]. These are available as components that
can also be used with SePIA and instructions on how to implement them is given on the
SePIA website. Users with a basic proficiency in a programming language are thus able
to utilize the workflow’s modular framework to implement and test custom components,
replace processes, or implement independent approaches to run in parallel.
All workflow scripts have a ’.and’ extension and are written in Anduril’s configuration
language based on Java. Users of any member of the Java programming language and
comparable languages like Python will, therefore, find it relatively straightforward to read
the pipeline execution scripts and learn how to further configure them.
SePIA’s sequence complementarity components discovered potential target mRNAs for
small RNAs withmiRNA-like features, providing association to biological function. It was
also used to increase the number of predicted targets of differentially expressed known
miRNAs. Sequence complementarity is widely accepted as a mechanism in which miR-
NAs identify targets. In Case II, 174 of the 408 differentially expressed miRNAs had
targets from our integrated target database with anti-correlated expression andminimum
fold-change of 0.5. Sequence complementarity added 54 miRNAs with potential bind-
ing motifs in the 3’UTR regions of their anti-correlated targets. The number includes
tumor suppressive (mir-205 and mir-143) and oncogenic miRNAs (mir-187 and mir-27b)
reported in breast cancer [53–56]. All 102 putative miRNA-target pairs from this addi-
tional set contained stringent binding motifs of 8mer, 7mer-m8 and 7mer-a1, presenting
this approach as an opportunity to explore viable cancer-relatedmiRNA regulation events
which have not yet been previously reported.
Correlation is an intuitive and straightforward approach to integrating miRNA and
mRNA expression. Putative miRNA targets supported by anti-correlated expression is
valuable information for planning any experimental work with miRNAs. However, to
identify functionally interesting networks of miRNAs and mRNAs from expression data,
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users may prefer more complex integrative approaches such as GenMiR++ [30]. An alter-
native and independently executable extension of the integration module demonstrates
how SePIA can streamline the preparation of necessary input files and execution of the
software. The output of the pipeline is a tab-delimited text file of miRNA-mRNA pairs
with GenMiR++ scores that can easily be used with further downstream analysis. The file
is included in the results reported on the SePIA website.
Tools available with SePIA are generally free to use. Most dependent software and pack-
ages are also included with the Docker installation of SePIA. However, while it is possible
to run MATLAB scripts with the workflow, MathWorks license prevents us from includ-
ing the software. Therefore, to implement a custom MATLAB script in a pipeline or to
use the optional integration pipeline with GenMiR++, users must first install the software
themselves.
SePIA pipeline scripts have been set up for the general process and analysis of a
two-case RNA-seq dataset. Users with such a dataset need only to change the inputs
and parameters outlined in the master settings file to run the pipeline. A dataset with
more than two cases will, however, affect how differential analysis is performed and
pipeline modification is required. The amount of modification to be done ultimately
depends on the programming experience of the user and willingness to troubleshoot a
pipeline script. A user can, at the very least, disable components in the analysis mod-
ule incompatible with their dataset by simply commenting them out. Similarly, a user
who wishes the pipeline to automatically output a ‘result’ file from a ‘componentA’
rather than retrieve the file manually from the execution folder must be able to add to
the end of the pipeline’s execution script the line ‘OUTPUT(componentA.result)’. The
pipeline’s modular design thus allows for both component execution and exclusion of
independent parts.
The underlying infrastructure of SePIA is designed to be scalable to large computational
resources dedicated to high-throughput sequencing analysis, and for optimal use with
batch processing. SePIA is capable of automating a time-memory trade-off by running in
parallel independent processes and allocating necessary memory or thread requirements
for each individual component. However, for some components the time-memory com-
plexity depends on the underlying implementation. To demonstrate, a subset of 8 samples
(4 normal, 4 tumor) was extracted from the TCGAmiRNAdataset to run on an Intel Xeon
X5650 processor with 90GB RAM and a 24-core. Using eight computational threads, pre-
processing, alignment, quantification, and differential expression analysis was performed
in less than 70 minutes. Novel miRNA discovery was fast with an average 40 minutes per
sample, but the single act of annotating putative novel miRNA regions with information
on their relative genomic location was time-intensive and required an additional 24 hours
to perform. Performance statistics is available in Additional file 1.
High-throughput sequencing of RNA is powerful but it is not without its challenges
[57]. With inevitable advancements in RNA-seq technology and in non-coding RNA
research, no workflow can be all-encompassing without an ability to evolve. The available
tools and modular design of SePIA is thus essential for implementation of novel RNA-seq
data processing and analysis tools to the workflow. For example, cross-linking technolo-
gies such as CLASH [58] make it possible to identify direct RNA-RNA hybridization.
The consequent influx of available experimentally validated interactions could be easily
included in the MirTPdb target database.
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With changes in RNA-seq technology and research comes changes in softwares
and algorithms used in pipelines. Often, these changes can break pipelines and pre-
vent reproducibility of results. Implementation of SePIA with a Docker container
ensures a reliable and static environment with all the required tools in compati-
ble software versions is always available to run SePIA. Furthermore, we will update
the Docker container with new releases of the SePIA workflow to ensure continued
usability.
Though users can install and update software manually, there is no guarantee com-
ponents using the software will continue to work correctly. Troubleshooting com-
ponents requires some programming skills and because SePIA is built on Anduril,
online support is available to the user. The bundle of RNA-seq components uses
versioning and it is possible to update to development versions of the RNA-seq
components.
Like RNA-seq, the SePIA workflow continues to be developed. Future releases will pro-
vide ready execution of additional tools, like the previously mentioned RSEM, as new
RNA-seq components. Version updates of STAR, Picard, and other listed tools may alter
component implementation in the workflow. Currently, version information is printed
to log files by most components available for use with SePIA but not by all. This will
be resolved in a future release to further ensure reproducibility of results. Fusion gene
detection will be a standardized process supporting the use of ChimeraScan [59], Fusion-
Catcher [60], and deFuse [61]. Novel and existing components will be developed to
support single-cell RNA data. Finally, methods to analyze both long and small non-coding
RNAs will be further explored.
Conclusion
We developed SePIA to address the need for a high-throughput workflow that pro-
vides a standard framework to process and analyze multiple RNA-seq data types,
primarily small (<200nt) and long (>200nt) RNA. The built-in pipeline infrastructure,
modular design, and range of independently executable components of the workflow
supports advanced methods-development and benefits users who regularly process
RNA-seq data. Pipeline scripts can be minimally configured with basic programming
knowledge. For novice users, the master settings file and ready-to-use computational
environment in Docker makes it easy to input data and run pipelines with minimal
effort.
Pipeline extensibility is a key advantage of the modular framework. It supports imple-
mentation of alternative computational approaches and the development of further
downstream analysis. To assist with functional studies of regulatory small RNAs, SePIA
features tools to query and maintain a SQLite database of annotated interactions, and to
discover putative novel miRNA-mRNA interactions.
The versatile design of the SePIA workflow makes it straightforward to incorporate
developments in RNA-seq technology and customized applications. Components for use
with the workflow are constantly being developed for further user convenience. SePIA
thus achieves a ’middle-ground’ approach to RNA-seq processing and analysis that har-
nesses the flexibility and computational resource management of bash scripting with the
approachable usability and ease of one-command pipeline execution of more graphical
user interfaces.
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